Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial

Ganesh Raghu, Rachel Million-Rousseau, Adele Morganti, Loïc Perchenet, Juergen Behr, N. Goh, A. Glanville, M. Musk, P. Hopkins, D. C. Lien, C. Chan, J. D. Rolf, P. Wilcox, P. G. Cox, H. Manganas, V. Cottin, D. Valeyre, B. Walleart, S. Andreas, C. NeurohrA. Guenther, N. Schönfeld, A. Koch, M. Kramer, R. Breuer, I. Ben-Dov, G. Fink, Y. Schwarz, C. Albera, M. Confalonieri, C. Saltini, S. Harari, M. Flezar, M. Greenblatt, G. J. Ras, F. Morell, J. L. Alvarez-Sala, A. Xaubet, A. Sueiro, M. J. Linares, M. Sköld, O. Kayacan, N. Mogulkoc, Andrew Chan, J. Chapman, J. Parambil, N. Ettinger, J. Golden, K. C. Meyer, J. J. Swigris, G. L. Yung, D. Antin-Ozerkis, P. K. Mohabir, L. J. Wesselius, J. De Andrade, F. Cordova, Z. Safdar, M. Wencel

Research output: Contribution to journalArticle

149 Scopus citations

Abstract

Idiopathic pulmonary fibrosis is a progressive, fatal disease. This prospective, randomised, double-blind, multicentre, parallel-group, placebo-controlled phase II trial (NCT00903331) investigated the efficacy and safety of the endothelin receptor antagonist macitentan in idiopathic pulmonary fibrosis. Eligible subjects were adults with idiopathic pulmonary fibrosis of

Original languageEnglish (US)
Pages (from-to)1622-1632
Number of pages11
JournalEuropean Respiratory Journal
Volume42
Issue number6
DOIs
StatePublished - Dec 1 2013

    Fingerprint

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Raghu, G., Million-Rousseau, R., Morganti, A., Perchenet, L., Behr, J., Goh, N., Glanville, A., Musk, M., Hopkins, P., Lien, D. C., Chan, C., Rolf, J. D., Wilcox, P., Cox, P. G., Manganas, H., Cottin, V., Valeyre, D., Walleart, B., Andreas, S., ... Wencel, M. (2013). Macitentan for the treatment of idiopathic pulmonary fibrosis: The randomised controlled MUSIC trial. European Respiratory Journal, 42(6), 1622-1632. https://doi.org/10.1183/09031936.00104612